The AstraZeneca PLC ADR AZN slid 7.39% to $68.46 Friday, on what proved to be an all-around poor trading session for the ...

AstraZeneca's (LON:AZN) stock up by 7.5% over the past three months. Since the market usually pay for a company’s long-term ...

AstraZeneca's (LON:AZN) stock up by 7.5% over the past three months. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s fundamentals to ...

AstraZeneca PLC closed 16.13% short of its 52-week high of £133.88, which the company reached on September 3rd.

Learn more about whether AstraZeneca PLC or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether AstraZeneca PLC or Corcept Therapeutics Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

AstraZeneca PLC has a one year low of $62.75 and a one year high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74. AstraZeneca (NASDAQ ...

A study undertaken by AstraZeneca reflects that AI-integrated CXR could be used as a preliminary step before low-dose ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...

AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

VANCOUVER, BC / ACCESS Newswire / April 3, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned ...

AstraZeneca shares have enjoyed moderate gains this year, helping to recover some of last year’s losses. But does it remain a ...